BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31728054)

  • 21. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
    Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
    Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
    Skoczen S; Klus K; Armata J; Kowalczyk J; Wisniewska-Slusarz H; Kolecki P; Derwich K; Matysiak M; Krauze A; Rokicka-Milewska R; Pawelec K; Boguslawska-Jaworska J; Juszczak K; Pisarek J; Sońta-Jakimczyk D; Tomaszewska R; Łuszczynska A; Wysocki M; Styczyński J
    Med Wieku Rozwoj; 2000; 4(1 Suppl 2):23-32. PubMed ID: 12021459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
    Glodkowska E; Bialas A; Jackowska T
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
    Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
    Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
    Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
    Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
    Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
    Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Matloub Y; Bostrom BC; Hunger SP; Stork LC; Angiolillo A; Sather H; La M; Gastier-Foster JM; Heerema NA; Sailer S; Buckley PJ; Thomson B; Cole C; Nachman JB; Reaman G; Winick N; Carroll WL; Devidas M; Gaynon PS
    Blood; 2011 Jul; 118(2):243-51. PubMed ID: 21562038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
    Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
    Mussolin L; Lovisa F; Gallingani I; Cavallaro E; Carraro E; Damanti CC; Vinti L; Sala A; Micalizzi C; Santoro N; Piglione M; Cellini M; Buffardi S; Buldini B; D'Amore ESG; Biffi A; Pillon M
    Br J Haematol; 2020 May; 189(3):e108-e111. PubMed ID: 32080837
    [No Abstract]   [Full Text] [Related]  

  • 40. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.